TECVAYLI demonstrates potential as frontline combination therapy for patients with newly diagnosed
December 9, 2024
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy Johnson